DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
L-THREONIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
L-THREONIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
75B0PMW2JF
Molecule Type:
Small molecule
Molecular Formula:
C4H8O5
Molecular Weight:
136.1
AlogP:
-2.21
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
3.0
Source:
SAMIDORPHAN
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Alcoholism; Feeding and Eating Disorders; Schizophrenia
Mu opioid receptor antagonist
SAMIDORPHAN
×
Maximum Phase:
2
First Approval:
None
UNII:
7W2581Z5L8
Molecule Type:
Small molecule
Molecular Formula:
C21H26N2O4
Molecular Weight:
370.45
AlogP:
1.25
PSA:
103.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
DAPORINAD
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell, Cutaneous; Melanoma
Nicotinamide phosphoribosyltransferase inhibitor
DAPORINAD
×
Maximum Phase:
2
First Approval:
None
UNII:
V71TF6V9M7
Molecule Type:
Small molecule
Molecular Formula:
C24H29N3O2
Molecular Weight:
391.52
AlogP:
3.93
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
8.0
Source:
PREDNYLIDENE
2
Small molecule
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Microscopic Polyangiitis
Unknown
PREDNYLIDENE
×
Maximum Phase:
2
First Approval:
None
UNII:
IF8PQP966U
Molecule Type:
Small molecule
Molecular Formula:
C22H28O5
Molecular Weight:
372.46
AlogP:
1.72
PSA:
94.83
HBD:
3.0
HBA:
#RotB:
2.0
Source:
TAS-106
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Head and Neck Neoplasms
DNA-directed RNA polymerase III subunit RPC1 inhibitor
TAS-106
×
Maximum Phase:
2
First Approval:
None
UNII:
Y3O05I09ZK
Molecule Type:
Small molecule
Molecular Formula:
C11H13N3O5
Molecular Weight:
267.24
AlogP:
-2.56
PSA:
130.83
HBD:
4.0
HBA:
#RotB:
2.0
Source:
VX-787
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VX-787
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-0941
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Hexokinase type IV activator
MK-0941
×
Maximum Phase:
2
First Approval:
None
UNII:
YZ1L3KR377
Molecule Type:
Small molecule
Molecular Formula:
C22H28N4O9S2
Molecular Weight:
556.62
AlogP:
2.41
PSA:
132.64
HBD:
2.0
HBA:
#RotB:
9.0
Source:
UK-500001
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase isozyme 4 inhibitor
UK-500001
×
Maximum Phase:
2
First Approval:
None
UNII:
YOG0PR3Q8J
Molecule Type:
Small molecule
Molecular Formula:
C26H24F3N3O4
Molecular Weight:
499.49
AlogP:
4.78
PSA:
100.55
HBD:
3.0
HBA:
#RotB:
6.0
Source:
RIVENPROST
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Prostanoid EP4 receptor agonist
RIVENPROST
×
Maximum Phase:
2
First Approval:
None
UNII:
1WBO45T413
Molecule Type:
Small molecule
Molecular Formula:
C24H34O6S
Molecular Weight:
450.6
AlogP:
2.94
PSA:
93.06
HBD:
2.0
HBA:
#RotB:
13.0
Source:
SODIUM CHOLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SODIUM CHOLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
NU3Y4CCH8Z
Molecule Type:
Small molecule
Molecular Formula:
C25H41NaO5
Molecular Weight:
444.59
AlogP:
3.84
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
4.0
Source:
AMINOPTERIN
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Endometrial Neoplasms; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis
Unknown
AMINOPTERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
JYB41CTM2Q
Molecule Type:
Small molecule
Molecular Formula:
C19H20N8O5
Molecular Weight:
440.42
AlogP:
0.24
PSA:
219.33
HBD:
6.0
HBA:
#RotB:
9.0
Source:
TOLIMIDONE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Tyrosine-protein kinase Lyn positive allosteric modulator
TOLIMIDONE
×
Maximum Phase:
2
First Approval:
None
UNII:
MU3JD8E9IS
Molecule Type:
Small molecule
Molecular Formula:
C11H10N2O2
Molecular Weight:
202.21
AlogP:
2.28
PSA:
55.24
HBD:
1.0
HBA:
#RotB:
2.0
Source:
552-02
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
552-02
×
Maximum Phase:
2
First Approval:
None
UNII:
81U49K9009
Molecule Type:
Small molecule
Molecular Formula:
C20H30ClN7O7S
Molecular Weight:
548.02
AlogP:
0.09
PSA:
194.99
HBD:
6.0
HBA:
#RotB:
10.0
Source:
TAK-715
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
MAP kinase p38 alpha inhibitor
TAK-715
×
Maximum Phase:
2
First Approval:
None
UNII:
WE92U03C5Z
Molecule Type:
Small molecule
Molecular Formula:
C24H21N3OS
Molecular Weight:
399.52
AlogP:
6.0
PSA:
54.88
HBD:
1.0
HBA:
#RotB:
5.0
Source:
AMITHIOZONE
2
Small molecule
Investigational
Unknown
Unknown
Mycobacterium avium-intracellulare Infection; Tuberculosis
Unknown
AMITHIOZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
MMG78X7SSR
Molecule Type:
Small molecule
Molecular Formula:
C10H12N4OS
Molecular Weight:
236.3
AlogP:
0.81
PSA:
79.51
HBD:
3.0
HBA:
#RotB:
3.0
Source:
TOVINONTRINE
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell; beta-Thalassemia
Phosphodiesterase 9A inhibitor
TOVINONTRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
W248Y1AKOR
Molecule Type:
Small molecule
Molecular Formula:
C21H26N6O2
Molecular Weight:
394.48
AlogP:
1.94
PSA:
88.41
HBD:
1.0
HBA:
#RotB:
4.0
Source:
RABUSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung
Serine/threonine-protein kinase Chk1 inhibitor
RABUSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3S9L1NU6U7
Molecule Type:
Small molecule
Molecular Formula:
C18H22BrN5O3
Molecular Weight:
436.31
AlogP:
2.87
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
5.0
Source:
ORGANON
2
Small molecule
Investigational
Unknown
Unknown
Substance-Related Disorders
Unknown
ORGANON
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H35N3O3
Molecular Weight:
437.58
AlogP:
4.78
PSA:
59.49
HBD:
1.0
HBA:
#RotB:
8.0
Source:
BERSACAPAVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis; Liver Diseases; Renal Insufficiency; Hepatitis B, Chronic
Unknown
BERSACAPAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C16H14F4N4O3S
Molecular Weight:
418.37
AlogP:
2.52
PSA:
103.99
HBD:
2.0
HBA:
#RotB:
5.0
Source:
GOVORESTAT
2
Small molecule
Investigational
Unknown
Unknown
Galactosemias
Unknown
GOVORESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C17H10F3N3O3S2
Molecular Weight:
425.41
AlogP:
3.76
PSA:
85.08
HBD:
1.0
HBA:
#RotB:
4.0
Source:
BRILACIDIN
2
Small molecule
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Membrane disrupting agent
BRILACIDIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I1679X069H
Molecule Type:
Small molecule
Molecular Formula:
C40H50F6N14O6
Molecular Weight:
936.92
AlogP:
3.68
PSA:
308.5
HBD:
12.0
HBA:
#RotB:
20.0
Source:
GLPG-1205
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis
G-protein coupled receptor 84 negative allosteric modulator
GLPG-1205
×
Maximum Phase:
2
First Approval:
None
UNII:
K9WR6LRA5D
Molecule Type:
Small molecule
Molecular Formula:
C22H22N2O4
Molecular Weight:
378.43
AlogP:
2.02
PSA:
62.58
HBD:
0.0
HBA:
#RotB:
3.0
Source:
LOTAMILAST
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Phosphodiesterase 4 inhibitor
LOTAMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
TO043KKB9C
Molecule Type:
Small molecule
Molecular Formula:
C26H24N4O5
Molecular Weight:
472.5
AlogP:
4.39
PSA:
111.67
HBD:
2.0
HBA:
#RotB:
7.0
Source:
IFETROBAN
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Muscular Dystrophy, Duchenne; Renal Insufficiency; Respiratory Tract Diseases
Unknown
IFETROBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
E833KT807K
Molecule Type:
Small molecule
Molecular Formula:
C25H32N2O5
Molecular Weight:
440.54
AlogP:
4.12
PSA:
101.66
HBD:
2.0
HBA:
#RotB:
11.0
Source:
AGANEPAG ISOPROPYL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AGANEPAG ISOPROPYL
×
Maximum Phase:
2
First Approval:
None
UNII:
R096XE6760
Molecule Type:
Small molecule
Molecular Formula:
C27H37NO4S
Molecular Weight:
471.66
AlogP:
6.45
PSA:
66.84
HBD:
1.0
HBA:
#RotB:
12.0
Source:
APLINDORE FUMARATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Dopamine D2 receptor partial agonist
APLINDORE FUMARATE
×
Maximum Phase:
2
First Approval:
None
UNII:
P13TV5A758
Molecule Type:
Small molecule
Molecular Formula:
C22H22N2O7
Molecular Weight:
426.43
AlogP:
2.11
PSA:
59.59
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ST-101
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Alzheimer Disease; Essential Tremor
Unknown
ST-101
×
Maximum Phase:
2
First Approval:
None
UNII:
7TTT61784C
Molecule Type:
Small molecule
Molecular Formula:
C15H12N2O
Molecular Weight:
236.27
AlogP:
1.85
PSA:
32.67
HBD:
0.0
HBA:
#RotB:
0.0
Source:
RELENOPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Constipation
Unknown
RELENOPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
SIS5BFO4WL
Molecule Type:
Small molecule
Molecular Formula:
C24H30ClFN4O4
Molecular Weight:
492.98
AlogP:
3.74
PSA:
119.91
HBD:
3.0
HBA:
#RotB:
9.0
Source:
AZD-9164
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
AZD-9164
×
Maximum Phase:
2
First Approval:
None
UNII:
977LWC4O5D
Molecule Type:
Small molecule
Molecular Formula:
C29H38FN2O2+
Molecular Weight:
465.63
AlogP:
4.92
PSA:
29.54
HBD:
0.0
HBA:
#RotB:
7.0
Source:
SJG-136
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Neoplasms
DNA cross-linking agent
SJG-136
×
Maximum Phase:
2
First Approval:
None
UNII:
KT0ZQ64X1A
Molecule Type:
Small molecule
Molecular Formula:
C31H32N4O6
Molecular Weight:
556.62
AlogP:
4.52
PSA:
102.26
HBD:
0.0
HBA:
#RotB:
8.0
Source:
SNX 5422
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Leukemia; Lymphoma; Neoplasms
Heat shock protein HSP90 inhibitor
SNX 5422
×
Maximum Phase:
2
First Approval:
None
UNII:
BF52J69Q8T
Molecule Type:
Small molecule
Molecular Formula:
C25H30F3N5O4
Molecular Weight:
521.54
AlogP:
3.37
PSA:
142.33
HBD:
3.0
HBA:
#RotB:
6.0
Source:
PETESICATIB
2
Small molecule
Investigational
Unknown
Unknown
Celiac Disease; Sjogren's Syndrome
Cathepsin S inhibitor
PETESICATIB
×
Maximum Phase:
2
First Approval:
None
UNII:
A26QO95U37
Molecule Type:
Small molecule
Molecular Formula:
C25H23F6N5O4S
Molecular Weight:
603.55
AlogP:
3.36
PSA:
125.16
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ATAGABALIN
2
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
Voltage-gated calcium channel modulator
ATAGABALIN
×
Maximum Phase:
2
First Approval:
None
UNII:
JT7957Q2FB
Molecule Type:
Small molecule
Molecular Formula:
C10H19NO2
Molecular Weight:
185.27
AlogP:
1.47
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
3.0
Source:
NESOLICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
NESOLICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
T2U4ZA62U4
Molecule Type:
Small molecule
Molecular Formula:
C18H18N4O4
Molecular Weight:
354.37
AlogP:
2.45
PSA:
114.28
HBD:
2.0
HBA:
#RotB:
5.0
Source:
ELLAGIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Follicular
Unknown
ELLAGIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
19YRN3ZS9P
Molecule Type:
Small molecule
Molecular Formula:
C14H6O8
Molecular Weight:
302.19
AlogP:
1.31
PSA:
141.34
HBD:
4.0
HBA:
#RotB:
0.0
Source:
1
2
…
106
107
108
109
110
111
112
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA